arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Arbutus Biopharma Corp

ABUS
$4.62 ▲ +0.08 (+1.76%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
39
Health
Weak
Bearish
auto_awesome

Analytical Summary

Arbutus Biopharma Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $895.2M
Dividend Yield
Revenue Growth 10054.5%
Op. Margin 94.3%
ROIC 51.3%
FCF / Share $-0.04
Trailing P/E 5.3x
Price / Book 3.5x
FCF Yield
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Aug 7, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$179.13M
↑ +10054.5%
Net Income Profit after all expenses
$169.69M
↑ +4618.0%
Operating Margin Operating profit as % of sales
94.3%
↑ +580.5% 0th
FCF / Share Free cash flow per share
$-0.04
↑ +40.4%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
18
Financial Health
97
Cash Quality
72

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 56 quarters